shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)

    RFA-DK-25-012

    National Institutes of Health

    Opening date 5 Jun 2024, 12:00AM

    Closing date 24 Oct 2024, 12:00AM

    Funding Opportunity Number: RFA-DK-25-012

    Opportunity Category: Discretionary

    CFDA Number(s): 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Jun 05, 2024 12:00:00 AM EDT

    Closing Date: Oct 24, 2024 12:00:00 AM EDT

    Award Ceiling: $5500000

    Award Floor: none

    Eligible Applicants: Small businesses

    Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. See full Notice of Funding Opportunity for additional details on eligibility. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

    Agency Name: National Institutes of Health

    Description: This Notice of Funding Opportunity (NOFO) is a non-competitive funding opportunity intended to fund a single award. The NIDDK is announcing its intent to issue a single source cooperative agreement to the University of Pennsylvania to continue the mission of the existing Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D). This NOFO will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; immunology and autoimmunity; collection, processing and multimodal analysis of human pancreatic tissues and immune compartments; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues and immune cells from patients with type 1 diabetes (T1D) or at risk of developing the disease, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through the existing PANC DB open-access resource database. HPAP-T1D is a component of the Human Islet Research Network or HIRN. HIRN was created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional human beta cell mass.

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept